North Star Asset Management Inc. Takes Position in Repligen Corporation $RGEN

North Star Asset Management Inc. purchased a new position in Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 77,561 shares of the biotechnology company’s stock, valued at approximately $10,582,000.

A number of other institutional investors have also made changes to their positions in the stock. United Capital Financial Advisors LLC bought a new stake in Repligen in the second quarter valued at about $380,756,000. Opti Capital Management LP bought a new position in Repligen during the fourth quarter worth about $2,399,209,000. Maverick Capital Ltd. acquired a new position in shares of Repligen during the 1st quarter worth about $178,946,000. Wasatch Advisors LP acquired a new position in shares of Repligen during the 1st quarter worth about $146,513,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after buying an additional 1,091,683 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Up 1.0%

NASDAQ RGEN opened at $182.03 on Friday. The firm has a market cap of $10.27 billion, a P/E ratio of 249.36, a P/E/G ratio of 3.29 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The stock’s 50-day moving average is $151.11 and its 200-day moving average is $132.79. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. During the same quarter in the previous year, the business posted $0.26 EPS. Repligen’s revenue for the quarter was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on RGEN shares. JPMorgan Chase & Co. increased their price target on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Evercore restated an “outperform” rating and set a $160.00 price objective on shares of Repligen in a report on Monday, July 6th. Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price for the company. HSBC cut their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Finally, Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.